Pivotal has announced the acquisition of Akcelis BVBA, a full-service provider of patient enrollment and retention solutions for clinical trials in the life sciences industry.
Patient recruitment is a well-known bottleneck in clinical trials as Sponsors can experience challenges across many therapeutic areas. United by a common culture, Akcelis brings experience to Pivotal to recruit and retain a patient population for difficult-to-recruit trials.
“This acquisition fits perfectly with our commitment to bringing innovation to the clinical development process to deliver efficiencies for our clients,” said Lidia Farr, VP Corporate Development and Finance at Pivotal. “Akcelis will bring advanced, proprietary and analytics-driven technology and services to customize the most efficient and cost-effective approach to significantly improve site selection and patient enrollment and retention strategies for our clients´ clinical trials. As we focus on delivering this value for our customers, we are pleased to welcome our new colleagues to Pivotal to become part of our solution-oriented culture and help advance drug development to improve patient lives.”
Providing analytics-driven services to many large and mid-sized pharmaceutical companies, Akcelis manages the entire patient recruitment lifecycle, from recruitment to enrollment to retention. These services utilize innovative, proprietary, and predictive software analytics to customize an efficient and effective approach to recruiting patients for a customer's clinical trial.
“Pivotal’s expertise in clinical research and Akcelis’ patient-centric approach to accelerate patient recruitment are the winning combination for scientifically elegant and patient-friendly clinical trials,” said Barbara D’haene and Nathalie Niclaus, Akcelis Managing Directors and Founders. “We look forward to positively impacting Pivotal’s clinical research excellence by implementing innovative digital patient recruitment strategies.”
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Reblozyl Misses Primary Endpoint in Phase III Myelofibrosis Trial but Shows Clinical Promise
July 21st 2025The Phase III INDEPENDENCE trial (NCT04717414) failed to meet its primary endpoint of achieving transfusion independence in patients with myelofibrosis-associated anemia treated with Reblozyl (luspatercept-aamt).
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.